Fig. 1
From: Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors
Elimination of senescent cells restores superior therapeutic effects by P→RT. Immunocompetent female INK-ATTAC mice bearing palpable M/D-driven tumors were randomly to allocated (1) no treatment; (2) focal radiation therapy (RT), (3) palbociclib (P) and their combination, optionally in the context of AP20187 administration, as indicated (a). Mice were followed for tumor growth and euthanatized when cumulative tumor surface reached 180–200 mm2, which was used to define overall survival (OS). Individual growth curves for cumulative tumors (b), progression-free survival (PFS, c) and OS (d) are reported. Differences in tumor growth (b) were assessed for statistical significance by a linear mixed effects model followed by simultaneous tests of general linear hypotheses Differences in PFS (c) and OS (d) were assessed for statistical significance by Gehan-Breslow-Wilcoxon test. Number of mice, hazard ratio (HR) with 95% confidence interval and p values are reported